Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The company did not disappoint.
CSX reported excellent earnings growth driven by double-digit volume gains. The company also remains upbeat about the future as it announced capital spending increases and additional share buy backs on the heels of another dividend increase.
Solid Third Quarter
CEO Michael Ward noted in the latest earnings release that the company saw volume growth in nearly every market as the economy continued to improve.
Total revenue increased 16% year-over-year driven by an overall volume gain of 10%. Growth was particularly strong in its automotive segment as vehicles sales improved significantly in the U.S.
Operating leverage helped CSX turn its 16% revenue increase into a 39% increase in operating income. Lower interest expense and fewer shares outstanding drove earnings per share up 48% to $1.08 in the third quarter. That beat the Zacks Consensus Estimate 4%.
Positive Outlook
Virtually every analyst raised their earnings estimates for 2010 and 2011 following the strong quarter. The flurry of positive estimate revisions propelled the stock to a Zacks #2 Rank (Buy) stock.
The 2010 Zacks Consensus Estimate is $4.02, corresponding to 40% growth over 2009 EPS. The 2011 estimate is 16% higher, at $4.65.
The company also announced it would be increasing its capital expenditures for the remainder of 2010 - a sign that management is optimistic about the company's future.
Returning Value to Shareholders
The company will also be using its capital to buy back additional shares. The company plans to spend around $646 million to repurchase its shares by the end of the first quarter of 2011.
The company also announced in September that it was raising its dividend. After holding its dividend steady for a few years, CSX has increased it 8 times since 2005 at an average annual clip of 39%.
The stock currently yields 1.6%.
Valuation
Shares trade at 14.7x forward earnings, a discount to the industry average of 19.0x. It has a PEG ratio of 1.3, also below the industry average, which is 1.7.
Its price to book ratio of 2.6 is twice that of the industry average. However, its return on equity of 16.4% exceeds the industry average of 7.0%, justifying the premium.
The company has a market cap of $22.5 billion. It is based in Jacksonville, Florida.
Get the full Analyst Report on CSX - FREE